International
The Novavax COVID-19 vaccine has been shown to be 51 per cent effective against the South African variant, according to a South African trial. The study of over 2,500 people found that predominantly mild-to-moderate COVID-19 developed in 15 people who received the vaccine compared to 29 in the placebo group, giving an overall efficacy of 49.4 per cent. However, the study included HIV-positive people who may have lower immune responses due to their ongoing treatment, and when these people were excluded the efficacy increased to 60.1 per cent. Most infections in the study were caused by the B.1.351 variant, often referred to as the South African variant, and among HIV-negative patients infected with the variant, the vaccine efficacy was 51 per cent.
From:
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
